Short answer
Definium Therapeutics, Inc. (DFTX) filed an 8-K current report with the SEC on September 14, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.2). Exhibit 99.1 furnished under Regulation FD, not treated as filed under Exchange Act Section 18.
Definium Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Exhibit 99.1 furnished under Regulation FD, not treated as filed under Exchange Act Section 18
- Exhibit excluded from automatic incorporation into Definium Therapeutics SEC filings
- Investor-relevant disclosure content resides in Exhibit 99.1, not the provided legal disclaimer
Item 8.01 · Other Events
- September 14, 2026 press release and Panorama topline data presentation filed as substantive exhibits
- Panorama study results likely represent a material clinical-development update for Definium Therapeutics
- Investors should review Exhibits 99.1 and 99.2 for efficacy, safety, endpoints, and next-step implications
Item EX-99.1 · Exhibit EX-99.2
- Panorama met primary and all key secondary endpoints in 245-patient Phase 3 GAD trial, reinforcing DT120 ODT’s regulatory case
- HAM-A placebo-adjusted improvement reached 5.1 points at Week 12, with p<0.0001 and Cohen’s d=0.64
- 100 µg dose showed 94.8% TEAE rate, but no drug-related serious adverse events and 10.4% discontinuation
- Pre-NDA meeting planned for 4Q 2026, with NDA filing anticipated in 1H 2027
- Development risk remains around FDA review and controlled-substance scheduling before potential commercialization
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Definium Therapeutics, Inc. 8-K filings
Get the next DFTX 8-K as it lands
Follow DFTX for push alerts, or ask the research agent what this filing means.